HCW Biologics Inc. (HCWB)
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
$22.69M
Dr. Hing C. Wong Ph.D.
44.00
Miramar, FL
Jul 20, 2021
-0.57
$-1.05
0.30
0.46
-697.59%
-0.82
-0.04
2.56
5.78
0.39
-90.02%
-146.76%
Similar stocks (9)
Eliem Therapeutics, Inc.
ELYM
PepGen Inc.
PEPG
Rezolute, Inc.
RZLT
Shattuck Labs, Inc.
STTK
Century Therapeutics, Inc.
IPSC
MediciNova, Inc.
MNOV
PMV Pharmaceuticals, Inc.
PMVP
Champions Oncology, Inc.
CSBR
Anebulo Pharmaceuticals, Inc.
ANEB
ETF Exposure (3)
iShares Micro-Cap ETF
IWC
0.00264%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (9)
Eliem Therapeutics, Inc.
ELYM
PepGen Inc.
PEPG
Rezolute, Inc.
RZLT
Shattuck Labs, Inc.
STTK
Century Therapeutics, Inc.
IPSC
MediciNova, Inc.
MNOV
PMV Pharmaceuticals, Inc.
PMVP
Champions Oncology, Inc.
CSBR
Anebulo Pharmaceuticals, Inc.
ANEB
ETF Exposure (3)
iShares Micro-Cap ETF
IWC
0.00264%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%